AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6224685
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg cotrimoxazole twice daily for ten days
Trial: 30417614
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA IV + 1 g TXA IA
Trial: 30417614
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA IV + 2 g TXA IA
Trial: 30417614
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA IV + 3 g TXA IA
Trial: 18789826
Drug: Late wake
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late wake therapy (LWT) (sleep 21:00-01:00 h)
Trial: 18789826
Drug: Early wake
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early wake therapy (EWT) (sleep 03:00-07:00 h)
Trial: 15655136
Drug: Eprosartan (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (600 mg OD)
Trial: 12847817
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor-based triple therapies
Trial: 12847817
Drug: H2-blockers based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-blockers based triple combinations lasting 10-14 days
Trial: 12847817
Drug: Classical triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical triple therapy (bismuth + 2 antimicrobials)
Trial: 12847817
Drug: Clarithromycin-based therapies
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based therapies
Trial: 12847817
Drug: Nitroimidazoles-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroimidazoles-based therapies
Trial: 12847817
Drug: Amoxicillin-based therapies
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-based therapies
Trial: 12847817
Drug: Doxycyclin-based therapies
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycyclin-based therapies
Trial: 31034254
Drug: High-dose KS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose KS drinks
Trial: 26555862
Drug: Adant® (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adant® (sodium hyaluronate injection)
Trial: 26555862
Drug: Artz® (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artz® (sodium hyaluronate injection)
Trial: 9031875
Drug: DTaP (diphtheria
RxNorm normalized name: Daptacel DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP (diphtheria and tetanus toxoid acellular pertussis vaccine)
Trial: 9031875
Drug: DTwP (diphtheria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP (diphtheria and tetanus toxoid whole-cell pertussis vaccine)
Trial: 30776134
Drug: JNJ-61178104 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-61178104 (0.1, 0.3, 1, 3, and 10 mg/kg IV; 1 mg/kg SC)
Trial: 30776134
Drug: JNJ-61178104 (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-61178104 (IV administration)
Trial: 30776134
Drug: JNJ-61178104 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-61178104 (1 mg/kg SC)
Trial: 30776134
Drug: JNJ-61178104 (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-61178104 (active treatment)
Trial: 29149379
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IT plus systemic)
Trial: 27386647
Drug: Tanshinone IIA
RxNorm normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanshinone IIA (T II A) at 80 mg/day for 3 successive days before oxaliplatin chemotherapy
Trial: 22298793
Drug: SLE with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLE with Therapy (480 patients)
Trial: 22298793
Drug: SLE No
RxNorm normalized name: AVOBENZONE 30 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 80 mg in 1 g TOPICAL AEROSOL, SPRAY [Cay Skin Isle Nourishing Body Mist SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLE No Therapy (75 patients)
Trial: 22298793
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) monotherapy (105 patients)
Trial: 22298793
Drug: Prednisone (PRED)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PRED) ≥20 mg (76 patients)
Trial: 22298793
Drug: PRED ≥20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED ≥20 mg + IS
Trial: 22298793
Drug: PRED ≥20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED ≥20 mg + CQ
Trial: 22298793
Drug: PRED ≥20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED ≥20 mg + IS + CQ
Trial: 18024208
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (supervised training for 10 weeks)
Trial: 15005875
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg, four times a day)
Trial: 9425399
Drug: Octreotide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (300 micrograms daily for 1 month)
Trial: 8214737
Drug: Flumazenil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.1 mg/kg) followed by placebo (NaCl 0.9%)
Trial: 8214737
Drug: Flumazenil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.1 mg/kg) followed by midazolam (0.1 mg/kg)
Trial: 8214737
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by midazolam (0.1 mg/kg)
Trial: 30821897
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement (100 mg Lactobacillus coagulans and fructo‐oligosaccharides, 2 tablets per day for 8 weeks)
Trial: 24620666
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise therapy (40-60 minutes a day, 3-4 days a week)
Trial: 15731536
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil (Group II)
Trial: 15731536
Drug: Intravenous isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isosorbide dinitrate (Group I)
Trial: 7659475
Drug: Whole-cell vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell vaccine (WCL)
Trial: 2485347
Drug: Modified formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified formula of parenteral nutrition
Trial: 2485347
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula of parenteral nutrition
Trial: 1173763
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparation SA (Eryfer)
Trial: 1173763
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparation SC (effervescent tablet)
Trial: 1173763
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparation SD (sustained release)
Trial: 1173763
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparation SE (enteric-coated pellets)
Trial: 27984823
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 25 mg 1 qd for maximal 7 days
Trial: 16616167
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to Treatment Inventory (BTI) administered to substance abusers
Trial: 11890592
Drug: Naloxone low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone low dose (LD) - bolus 27 microg/kg; continuous 50 microg/kg/hr
Trial: 11890592
Drug: Naloxone high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone high dose (HD) - bolus 54.5 microg/kg; continuous 100 microg/kg/hr
Trial: 9399710
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment strategies
Trial: 7699476
Drug: GCNS monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GCNS monitoring with daily patient visits
Trial: 3109663
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg initially, followed by 4 mg every six hours)
Trial: 31724348
Drug: Estazolam (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam (medication group)
Trial: 23707115
Drug: AMPAR peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMPAR peptide assay (0.05-0.40 ng/mL for controls, 1.0-8.5 ng/mL for concussions)
Trial: 23707115
Drug: AMPAR peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMPAR peptide values in athletes with multiple concussions (2.0-12.0 ng/mL)
Trial: 15208586
Drug: Inhaled fluticasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone, 500 microg twice daily for 14 days
Trial: 9636522
Drug: MMF 1
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1 g
Trial: 9636522
Drug: MMF 2
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2 g (mean dose adjusted to 1.5 g by 6 months)
Trial: 8160943
Drug: Fentanyl (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (same dose) plus clonidine 4 micrograms.kg-1 in 20 min + 2 micrograms.kg-1.h-1 (group B)
Trial: 8160943
Drug: Fentanyl plus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group C)
Trial: 8160943
Drug: Fentanyl plus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group D)
Trial: 31077432
Drug: PK-guided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided dosing of paclitaxel
Trial: 31077432
Drug: BSA-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSA-based dosing of paclitaxel
Trial: 28259326
Drug: Low-dose screening
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose screening chest CT
Trial: 23850386
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied on the contralateral thigh
Trial: 21346159
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose remifentanil (0.2 μg · kg(‐1) · min(‐1))
Trial: 21346159
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose remifentanil (0.4 μg · kg(‐1) · min(‐1))
Trial: 18432177
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) with antiproliferative drugs attached via polymers
Trial: 8666176
Drug: Dobutamine echocardiography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine echocardiography (TED) with incremental dobutamine infusion: 5 to 40 ncg/kg/min, continued with atropine 0.25 to 1 mg iv if necessary
Trial: 8666176
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TED and TE results
Trial: 1632167
Drug: Glycopyrrolate (0.003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.003 and 0.0075 mg/kg)
Trial: 1632167
Drug: Atropine (0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.006 and 0.015 mg/kg)
Trial: 25980345
Drug: Adjunctive raloxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive raloxifene treatment (120 mg per day)
Trial: 22289524
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil/leucovorin (NCT group)
Trial: 22289524
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy alone (non-NCT group)
Trial: 15228463
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide IV
Trial: 15228463
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg metoclopramide IV (up to 32 mg)
Trial: 11390121
Drug: Aerodiol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerodiol 300 microg, once daily
Trial: 2890156
Drug: Psychoactive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoactive agents
Trial: 26210542
Drug: NOCTP: non-operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOCTP: non-operative caries treatment programme
Trial: 16942960
Drug: Mental reinstatement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental reinstatement of the treatment context before follow-up test
Trial: 16942960
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy in one of two contexts
Trial: 12940592
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GK501) 120 mg
Trial: 9249121
Drug: Ketoprofen (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (1.5 mg/kg) + Morphine (0.1 mg/kg)
Trial: 9249121
Drug: Ketoprofen (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (1.5 mg/kg)
Trial: 8322695
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 mg orally)
Trial: 8322695
Drug: Nitroglycerin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.5 mg sublingually)
Trial: 3011329
Drug: Enalapril (10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10‐40 mg/day, p.o., for 6 weeks)
Trial: 3011329
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/day, p.o.) alone for 2 weeks
Trial: 3011329
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/day, p.o.) in combination with propranolol (80‐160 mg/day, p.o.) for 4 weeks
Trial: 26587088
Drug: Standard methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methods to determine medication dosing (control)
Trial: 20638190
Drug: PENTOCLO (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENTOCLO (800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week)
Trial: 15324522
Drug: fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 200 mg + ezetimibe 10 mg
Trial: 15324522
Drug: fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 200 mg
Trial: 10926898
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine extract (1 g/day, equivalent to 375 mL of red wine)
Trial: 10926898
Drug: Quercetin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (30 mg/day)
Trial: 8359587
Drug: Recombinant insulin-like
RxNorm normalized name: Recombinant human insulin-like growth factor 1
DrugBank: Recombinant human insulin-like growth factor 1 (DB18684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant insulin-like growth factor I (40 micrograms/kg body weight)
Trial: 3024866
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg orally)
Trial: 3024866
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naloxone infusion (180 min after loperamide administration)
Trial: 24937541
Drug: Pioglitazone (PIO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO; 15 mg for 6 weeks, then 30 mg daily)
Trial: 22431401
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation and emotion skills training (CREST) plus treatment as usual
Trial: 17699008
Drug: HPV-16/18 L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 L1 protein viruslike particle AS04 candidate vaccine (n = 1088)
Trial: 17699008
Drug: Control hepatitis
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control hepatitis A vaccine (n = 1101)
Trial: 9990561
Drug: Clozapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (300 mg/day, increased to 600 and 900 mg/day if tolerated)
Trial: 9990561
Drug: Conventional neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neuroleptic (initial treatment for 6 weeks)
Trial: 22955359
Drug: L. salivarius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. salivarius LS01 (probiotic)
Trial: 9316673
Drug: L-Dopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa/benserazide
Trial: 2465445
Drug: 3-OH-HQ 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-OH-HQ 225 mg
Trial: 2465445
Drug: 3-OH-HQ 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-OH-HQ 450 mg
Trial: 2465445
Drug: 3-OH-HQ 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-OH-HQ 900 mg
Trial: 29144152
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and psychological treatment
Trial: 26706860
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug and non-drug antidepressive treatment (control group)
Trial: 8876264
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day prednisolone
Trial: 1615179
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (5 mg) as one puff q.d.s. via inhaler
Trial: 6380212
Drug: Phenobarbital 12
RxNorm normalized name: phenobarbital 120 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 12 mg/kg
Trial: 6380212
Drug: Phenobarbital 4
RxNorm normalized name: phenobarbital 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 4 mg/kg
Trial: 6380212
Drug: Phenobarbital 8
RxNorm normalized name: phenobarbital 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 8 mg/kg
Trial: 29161199
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray (64 μg/mL) twice daily for 6 weeks
Trial: 18080054
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (COT) with rabeprazole 20 mg
Trial: 18080054
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy (ODT) with rabeprazole 20 mg
Trial: 12168126
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml line-clearing volume
Trial: 12168126
Drug: 3.0 ml
RxNorm normalized name: HYDROGEN PEROXIDE 3.0 mL in 100 mL TOPICAL SPRAY [aramark Hydrogen Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 ml line-clearing volume
Trial: 12168126
Drug: 4.0 ml
RxNorm normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 ml line-clearing volume
Trial: 7876649
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 6 months
Trial: 7876649
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 12 months
Trial: 7876649
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (HM175)
Trial: 23464715
Drug: Oral synbiotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral synbiotic (Agri-King Synbiotic, AKSB)
Trial: 20890244
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg monthly) plus PDT
Trial: 19660610
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus Fenofibrate (20 mg simvastatin + 160 mg fenofibrate)